Bayer’s (BAYN) Neutral Rating Reaffirmed at DZ Bank

DZ Bank restated their neutral rating on shares of Bayer (FRA:BAYN) in a research report released on Monday morning, Borsen Zeitung reports.

Other research analysts have also issued reports about the company. Baader Bank set a €123.00 ($143.02) target price on Bayer and gave the stock a buy rating in a research report on Wednesday, August 7th. Nord/LB set a €64.00 ($74.42) target price on Bayer and gave the stock a neutral rating in a research report on Friday, October 4th. Deutsche Bank set a €70.00 ($81.40) target price on Bayer and gave the stock a neutral rating in a research report on Friday, August 9th. Berenberg Bank set a €67.00 ($77.91) target price on Bayer and gave the stock a neutral rating in a research report on Wednesday, July 31st. Finally, Morgan Stanley set a €82.00 ($95.35) target price on Bayer and gave the stock a buy rating in a research report on Tuesday, September 17th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of €79.90 ($92.91).

Shares of Bayer stock opened at €65.22 ($75.84) on Monday. The stock has a 50-day moving average price of €65.68 and a 200 day moving average price of €60.49. Bayer has a 1 year low of €91.58 ($106.49) and a 1 year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Featured Article: Trade Deficit

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.